[go: up one dir, main page]

WO2010074083A1 - Immunodosage utilisant un transfert d'énergie par résonance de fluorescence et des plasmons de surface - Google Patents

Immunodosage utilisant un transfert d'énergie par résonance de fluorescence et des plasmons de surface Download PDF

Info

Publication number
WO2010074083A1
WO2010074083A1 PCT/JP2009/071331 JP2009071331W WO2010074083A1 WO 2010074083 A1 WO2010074083 A1 WO 2010074083A1 JP 2009071331 W JP2009071331 W JP 2009071331W WO 2010074083 A1 WO2010074083 A1 WO 2010074083A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
thin film
metal thin
antigen
fluorescence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2009/071331
Other languages
English (en)
Japanese (ja)
Inventor
直樹 日影
高敏 彼谷
英隆 二宮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Konica Minolta Inc
Original Assignee
Konica Minolta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Konica Minolta Inc filed Critical Konica Minolta Inc
Priority to JP2010544084A priority Critical patent/JP5720248B2/ja
Publication of WO2010074083A1 publication Critical patent/WO2010074083A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6432—Quenching

Definitions

  • the present invention relates to an immunoassay method using surface plasmon and fluorescence resonance energy transfer, and a system and kit for the assay. More specifically, the present invention relates to an immunoassay method using surface plasmon based on the principle of surface plasmon excitation enhanced fluorescence spectroscopy (SPFS; Surface Plasmon-field enhanced Fluorescence Spectroscopy) and applying FRET technology to fluorescence detection.
  • SPFS surface plasmon excitation enhanced fluorescence spectroscopy
  • SPFS surface plasmon excitation enhanced fluorescence spectroscopy
  • irradiation is performed by generating a dense wave (surface plasmon) on the surface of the metal thin film under the condition that the irradiated laser light is attenuated by total reflection (ATR) on the surface of the metal thin film.
  • ATR total reflection
  • the amount of photons contained in the laser light is increased to several tens to several hundreds times (the electric field enhancement effect of the surface plasmon), and this effectively excites the fluorescent dye in the vicinity of the metal thin film, resulting in a trace amount and / or extremely low concentration of the analog. It is a method that can detect light.
  • Patent Document 1 discloses an electric field enhanced by surface plasmon by disposing a primary antibody-immobilized film using carboxymethyldextran on the surface of a metal substrate. Discloses a method for detecting a fluorescent dye associated with an antigen.
  • analyte for example, a target antigen
  • the amount of fluorescent dye in the complex associated with the antigen in the assay is also extremely small, and this becomes a bottleneck of the amount of fluorescence generated. Even if plasmon electric field enhancement is used, the amount of fluorescence signal is not enhanced, and it is difficult to improve assay sensitivity.
  • Patent Document 2 examines amplifying signals and reducing non-specific reactions by complexly combining a reaction with an apoenzyme or holoenzyme and an immune reaction on a sensor substrate.
  • extremely precise molecular orientation technology is a prerequisite, and if the apo / holoenzyme reaction is preferential or dominant over the immune reaction, the risk that the measurement system itself cannot be established High nature.
  • FRET fluorescence resonance energy transfer
  • the assay method of the present invention (FIG. 2) constituted by a mechanism in which substantially only the immune complex emits light was completed.
  • the present invention has excellent specificity that is indispensable for an immunoassay, and preferably combines surface plasmon and fluorescence resonance energy transfer with high sensitivity and high accuracy by independently combining an immune reaction field and a detection field. It is an object to provide an assay method, system and kit for the assay.
  • the present invention which is a highly sensitive assay method capable of specifically enhancing and measuring only the fluorescence of the immune complex even with a very small amount of target antigen, has the following constitution. That is, An immunoassay method for measuring the amount of antigen in a specimen using a primary antibody bound with a fluorescent dye as a donor molecule and a secondary antibody bound with a fluorescent dye as an acceptor molecule, comprising at least Step (a): An antigen-antibody reaction is caused between the antigen contained in the specimen and both the primary antibody and the secondary antibody, and the immune complex sandwiched by the two antibodies is used as a metal thin film substrate.
  • FRET fluorescence resonance energy transfer
  • the specimen and the secondary antibody are brought into contact, and then the secondary antibody bound with the antigen is brought into contact with the metal thin film substrate on which the primary antibody is immobilized. It is desirable to fix it on a metal thin film substrate.
  • a metal thin film substrate on which the primary antibody is immobilized is brought into contact with a specimen, and then the secondary antibody is applied to the substrate, whereby the immune complex is placed on the metal thin film substrate. It may be fixed.
  • the primary antibody and the secondary antibody are brought into contact with a specimen, and the formed immune complex is brought into contact with a metal thin film substrate, whereby the immune complex is placed on the metal thin film substrate. It may be fixed.
  • the donor molecule and acceptor molecule are a FRET pair.
  • FRET pair Preferably from Alexa Fluor647 / Cy5.5, HiLyte Fluor647 / Cy5.5, fluorescein isothiocyanate (FITC) / tetramethylrhodamine isothiocyanate (TRITC), R-phycoerythrin (R-PE) / allophycocyanin (APC) The selected FRET pair.
  • the metal thin film substrate is a plasmon excitation sensor substrate having at least a transparent flat substrate and a metal thin film formed on one surface thereof.
  • the laser light irradiation by the surface plasmon excitation fluorescence method means that the laser light is irradiated via the prism from the other transparent substrate surface on which the metal thin film of the plasmon excitation sensor is not formed. It is.
  • kits for the above assay comprising at least a plasmon excitation sensor, a primary antibody bound with a fluorescent dye serving as a donor molecule, which is an antibody immobilized on the surface of the metal thin film substrate,
  • an immune antibody reaction is caused by generating a sandwich-type antigen-antibody reaction between the primary antibody, the antigen in the sample, and the secondary antibody. It is a kit used for carrying out the step of forming a complex.
  • the metal thin film is formed of at least one metal selected from the group consisting of gold, silver, aluminum, copper and platinum.
  • the plasmon excitation sensor is composed of the metal thin film and the transparent flat substrate, and further has a spacer layer, and the spacer layer is formed on the other surface of the metal thin film that is not in contact with the transparent flat substrate. It is preferable.
  • the spacer layer is preferably SAM (Self Assembled Monolayer).
  • the present invention includes at least A primary antibody bound to a fluorescent dye serving as a donor molecule, which is immobilized on a metal thin film substrate of a plasmon excitation sensor, A secondary antibody to which a fluorescent dye serving as an acceptor molecule is bound, A plasmon excitation sensor, a light source for surface plasmon excitation fluorescence method, and a fluorescence detector, and cause a sandwich-type antigen-antibody reaction between both the primary antibody and the secondary antibody and the antigen contained in the specimen.
  • the plasmon excitation sensor emits light by fluorescence resonance energy transfer from the fluorescent dye of the primary antibody excited by irradiating the immune complex immobilized on the metal thin film substrate with laser light by the surface plasmon excitation fluorescence method.
  • an immunoassay system that measures the amount of the antigen by measuring the amount of fluorescence of the acceptor molecule.
  • the conventional sandwich immunoassay method When detecting an extremely small amount of analyte, the conventional sandwich immunoassay method had a small amount of fluorescence signal and relatively increased background noise, so that the S / N ratio was deteriorated. Even when SPFS is introduced into the detection system, a mismatch occurs between the surface plasmon electric field enhancement (example of electric field enhanced photon amount) and the amount of fluorescent dye (example of fluorescent photon amount) of a very small amount of analyte, resulting in a sensitivity limit. There was a possibility.
  • the immunoassay method of the present invention a mechanism in which only the immune complex emits light by providing luminescence enhancement based on the FRET technique in detection with a plasmon excitation sensor (SPFS) is provided. Furthermore, it is desirable to make the immune reaction field and the detection field independent. This increases the difference between the excitation wavelength and the fluorescence wavelength and increases the fluorescence signal emitted from the immune complex. On the other hand, fluorescence such as secondary antibodies that are not involved in the immune reaction is not detected, so background noise is generated. Reduced to allow for high S / N ratio assays.
  • SPFS plasmon excitation sensor
  • analyte eg, target antigen
  • concentration of 10 ⁇ 18 mol (1 amol / L) to 10 ⁇ 12 mol (1 pmol / L) per liter from a sample containing an analyte (eg, target antigen) at a concentration of 10 ⁇ 18 mol (1 amol / L) to 10 ⁇ 12 mol (1 pmol / L) per liter,
  • the analyte can be detected with high sensitivity and high accuracy.
  • the FRET pairs When the FRET pairs are separated from each other by 10 nm or more, the FRET disappears and the emission of the acceptor on the secondary antibody is significantly attenuated. Therefore, only the fluorescence derived from the immune complex is substantially detected through FRET that is expressed when the donor / acceptor pair is at an appropriate distance, and a washing operation (B / F separation) is not required. .
  • the assay of the present invention can completely separate the immune reaction field and the fluorescence detection field, the immune reaction conditions and the detection conditions can be optimized separately, and is less susceptible to scattering noise and background noise. Furthermore, since it has three sensitivity amplification mechanisms, namely, immune reaction optimization, chemical amplification and physical amplification, it is possible to provide an extremely sensitive and highly accurate SPFS / FRET immunoassay.
  • FIG. 1 schematically shows a conventional sandwich immunoassay.
  • the fluorescent dye (50) is labeled only on the secondary antibody (40, 41, 42).
  • the secondary antibody (42) non-specifically bound by excitation (100) and the fluorescent dye (50) of the free secondary antibody (41) also emit light, increasing noise (300). For this reason, a cleaning operation is required.
  • FIG. 2 is a diagram schematically showing a sandwich immunoassay using SPFS / FRET of the present invention.
  • the primary antibody (20) and the secondary antibody (40, 41, 42) are labeled with a fluorescent dye (60) serving as a donor molecule and a fluorescent dye (70) serving as an acceptor molecule, respectively.
  • the secondary antibody (40) oriented at an appropriate distance from the excited (100) fluorescent dye (60) of the primary antibody (20) only when the immune complex (500) to be detected is formed
  • the energy is transferred to the fluorescent dye (70) and emits fluorescence (FRET (400)).
  • FRET fluorescence
  • analyte is a substance to be assayed, that is, a test substance, and refers to a relatively large molecule mainly designated as “antigen”. Low molecular weight compounds (haptens) such as substances can also be targeted.
  • the “fluorescent dye” is a general term for substances that emit fluorescence by irradiating predetermined excitation light or using the electric field effect in the present invention. Including luminescence.
  • SPFS Surface plasmon excitation enhanced fluorescence spectroscopy or surface plasmon-field enhanced fluorescence spectroscopy
  • FRET fluorescence resonance energy transfer
  • the immunoassay method of the present invention comprises: An immunoassay method for measuring the amount of antigen in a specimen using a primary antibody bound with a fluorescent dye as a donor molecule and a secondary antibody bound with a fluorescent dye as an acceptor molecule, comprising at least Step (a): An antigen-antibody reaction is caused between the antigen contained in the specimen and both the primary antibody and the secondary antibody, and the immune complex sandwiched by the two antibodies is used as a metal thin film substrate.
  • FRET fluorescence resonance energy transfer
  • the second half of the assay is to detect the immune complex thus formed with high sensitivity. That is, the fluorescent dye of the donor molecule is excited by SPFS for the purpose of specifically detecting only a small amount of the immune complex. From the other surface of the substrate where the thin film is not formed, the immune complex is irradiated with a laser beam via a prism, and the FRET phenomenon occurs between the fluorescent dye and the acceptor molecule of the excited donor molecule. To express. The fluorescence of the acceptor molecule of the secondary antibody excited by this FRET is detected by a plasmon excitation sensor, and the amount of emitted fluorescence is obtained.
  • the immunoassay method of the present invention employs a method in which the immune complex formed as described above is detected with high sensitivity by SPFS / FRET, but a primary dye conjugated with a fluorescent dye serving as a donor molecule for FRET expression.
  • a secondary antibody to which an antibody and a fluorescent dye as an acceptor molecule are bound is used.
  • the primary antibody used in the assay of the present invention is an antibody that can recognize and bind to an analyte (for example, a target antigen) contained in a specimen. At the same time, the primary antibody binds a fluorescent dye that becomes the FRET donor molecule. Further, the primary antibody is immobilized on the surface of the metal thin film substrate constituting the plasmon excitation sensor, preferably a spacer layer, for example, SAM (Self Assembled Monolayer), or immobilized on the substrate during fluorescence detection. (FIG. 2).
  • the secondary antibody is a specific antibody against the same target antigen as the primary antibody, and is bound with a fluorescent dye serving as the FRET acceptor molecule.
  • the secondary antibody recognizes and binds to an epitope of the same target antigen (however, an epitope different from that of the primary antibody).
  • the primary antibody and the secondary antibody specifically bind to different sites of the same antigen to form a sandwich-type immune complex, and this is immobilized on the surface of the metal thin film substrate constituting the plasmon excitation sensor. This is the first half of the immunoassay.
  • the secondary antibody may bind non-specifically to the primary antibody but not the target antigen, but in this case it is necessary to prevent FRET from being expressed.
  • antibody includes polyclonal or monoclonal antibodies, antibodies obtained by gene recombination, and antibody fragments.
  • AFP anti- ⁇ fetoprotein
  • CEA anti-carcinoembryonic antigen
  • the secondary antibody may be a monoclonal antibody or a polyclonal antibody.
  • the primary antibody is a monoclonal antibody
  • the secondary antibody is preferably a monoclonal antibody that recognizes an epitope that the primary antibody does not recognize, or a polyclonal antibody.
  • the primary antibody immobilized on the plasmon excitation sensor is an AFP monoclonal antibody
  • the secondary antibody that binds to it is a monoclonal antibody that can recognize and bind to an antigen that competes with AFP contained in the specimen. Requires an antibody or polyclonal antibody.
  • Preferable examples include immunoglobulins (antibodies) each consisting of a pair of H and L chains, their Fabs (antigen-binding fragments), or similar protein fragments showing effective epitope affinity. .
  • analyte is a low molecular weight substance (such as a hapten) that is difficult to be recognized as an epitope having a different antigen
  • Fab, scFv, or the like as a binding partner instead of the antibody. Details of such a non-competitive immunoassay are disclosed in US Pat.
  • “Specimen” refers to a biological sample, environmental sample, or the like that has been pretreated as required for this assay.
  • the sample include blood, serum, plasma, urine, nasal fluid, saliva, feces, body cavity fluid (eg, cerebrospinal fluid, ascites fluid, pleural effusion), and the like, and appropriately diluted with a desired solvent, buffer solution, etc. May be.
  • body cavity fluid eg, cerebrospinal fluid, ascites fluid, pleural effusion
  • blood, serum, plasma, urine, nasal fluid and saliva are preferred. These may be used alone or in combination of two.
  • Antigen contained in the specimen is a molecule or molecular fragment that can be specifically recognized (or recognized) and bound by the secondary antibody and the primary antibody immobilized (or immobilized) on the substrate surface. It is.
  • molecules or “molecular fragments” include nucleic acids (DNA that may be single-stranded or double-stranded, RNA, polynucleotides, oligonucleotides, PNA (peptide nucleic acids), etc., Or nucleosides, nucleotides and their modified molecules), proteins (polypeptides, oligopeptides, etc.), amino acids (including modified amino acids), carbohydrates (oligosaccharides, polysaccharides, sugar chains, etc.), lipids, or modifications thereof Examples thereof include molecules, complexes, and the like. Specifically, it may be a carcinoembryonic antigen such as AFP ( ⁇ -fetoprotein), a tumor marker, a signal transducing substance, a hormone, and the like,
  • an antigen-antibody reaction is caused by bringing the sample into contact with the antibody.
  • the temperature is usually 4 to 50 ° C., preferably 10 to 40 ° C.
  • the time is usually 0.5 to 180 minutes, preferably 5 to 60 minutes.
  • a positive control and a negative control are also performed at the same time, it is convenient to perform on a multi-well plate.
  • step (a) of immobilizing the formed immune complex on the plasmon excitation sensor metal thin film substrate there are the following three modes for causing an antigen-antibody reaction.
  • the specimen is brought into contact with the secondary antibody, and then the secondary antibody bound with the antigen is brought into contact with the metal thin film substrate (of the plasmon excitation sensor) on which the primary antibody is immobilized.
  • a method of immobilizing the immune complex on a metal thin film substrate (for a plasmon excitation sensor) In the step (a), the primary antibody and the secondary antibody are brought into contact with a specimen, and the formed immune complex is brought into contact with a metal thin film substrate (of a plasmon excitation sensor) to thereby form the immune complex.
  • This is a method of immobilizing on a metal thin film substrate (for a plasmon excitation sensor).
  • the immune complex formed is immobilized by some interaction that occurs between the primary antibody and the binding partner on the metal thin film substrate (of the plasmon excitation sensor) or on the spacer layer.
  • the interaction may be, for example, a gold-S bond, biotin- (strept) avidin, or an antibody against the primary antibody.
  • the above-mentioned “contact” is a state in which the surface on which the primary antibody of the plasmon excitation sensor is immobilized is immersed in a liquid (reaction solution) that has been applied or sent. This refers to bringing the immune complex contained in the liquid into contact with the metal thin film substrate or spacer layer of this plasmon excitation sensor.
  • reaction solution a liquid
  • the specific method will be described in detail in the section “Plasmon Excitation Sensor” below.
  • the “contact” between the reaction solution and the plasmon excitation sensor includes, for example, an immune complex formed in the liquid supply circulating in the flow path, and the primary antibody of the plasmon excitation sensor is immobilized.
  • a mode in which the plasmon excitation sensor and the reaction liquid in the step (a) are brought into contact with each other is preferable. This is easily realized by fixing the plasmon excitation sensor to the flow path so that the surface on which the primary antibody is fixed becomes a part of the flow path.
  • the first method should be adopted when the primary antibody needs to be stably immobilized on the substrate surface.
  • the second method when the surface of the substrate can easily bind the primary antibody that forms an immune complex with the secondary antibody, or when the spacer described below is installed and in such a state Can be adopted. Since the primary antibody, the secondary antibody and the antigen are in a free state in the solution and cause an antigen-antibody reaction, there is a feature that there is no interference such as steric hindrance.
  • Both of these systems are characterized in that the immune reaction field and the detection field of the formed immune complex are independent of each other. Therefore, there is an advantage that a washing operation for the purpose of B / F (binding / free) separation is not required. It greatly contributes to the reduction of fluorescence background noise.
  • Another remaining format is similar to the conventional sandwich immunoassay format, where the primary antibody is a solid phase antibody
  • a method in which the immune complex is immobilized on a metal thin film substrate of a plasmon excitation sensor by contacting the specimen with a metal thin film substrate on which the primary antibody is immobilized, and then applying a secondary antibody to the substrate. is there.
  • the secondary antibody to which the fluorescent dye of the acceptor molecule is bound is applied to the plasmon excitation sensor metal thin film substrate in contact with the specimen.
  • Contact in the case of “contacting the metal thin film substrate on which the primary antibody is immobilized and the specimen, and then applying the secondary antibody to the substrate” is as described above. That is, a solution containing the secondary antibody is brought into contact with the substrate by liquid feeding or the like.
  • a sample solution is applied to the substrate (or spacer layer), the substrate is washed with a washing buffer, and then a secondary antibody solution is added in a predetermined amount to the surface of the substrate on which the primary antibody is immobilized. For a certain period of time. An antigen-antibody reaction occurs between the primary antibody and the secondary antibody that bind to the antigen contained in the specimen.
  • the washing operation is an operation of washing the surface after applying the specimen to the substrate surface having the primary antibody. Therefore, the washing operation is preferably included before and / or after the application of the secondary antibody.
  • a surfactant such as Tween 20 or Triton X100 is dissolved in the same solvent or buffer solution, and preferably contains 0.00001 to 1% by weight.
  • This mode should be adopted when the primary antibody needs to be stably immobilized on the surface of the substrate and it is preferable to first bind the primary antibody and the antigen.
  • the temperature is usually 4 to 50 ° C., preferably 10 to 40 ° C.
  • the time is usually 0.5 to 180 minutes, preferably 5 to 60 minutes.
  • the immune complex is immobilized on the metal thin film surface of the metal thin film substrate.
  • a spacer layer is installed as described later, it may be fixed on the surface of the spacer layer.
  • the plasmon excitation sensor includes a metal thin film and a transparent flat substrate, and a spacer layer may be formed on the other surface of the metal thin film that is not in contact with the transparent flat substrate.
  • a method for immobilizing the primary antibody on the substrate surface an optimal crosslinking method according to the terminal functional group on the substrate surface can be selected. Further, depending on the properties of the substrate surface, a method of directly adsorbing directly to the surface can also be mentioned as an effective means.
  • a conventionally used fluorescent labeling method for proteins see, for example, JP-A-6-109732
  • the fluorescent dye molecule and an appropriate cross-linking agent such as silane are used. What is necessary is just to make it couple
  • the crosslinking agent include N-succinimidyl 3- (2-pyridyldithio) propionate (SPDP) and derivatives thereof, m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester and derivatives thereof, and the like.
  • the carboxyl group of the fluorescent dye is converted into water-soluble carbodiimide (WSC) (for example, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDC)) and N-hydroxysuccinimide ( NHS) and then esterifying the carboxyl group and the amino group of the antibody protein by dehydration using water-soluble carbodiimide; immobilizing the antibody protein and fluorescence having an isothiocyanate and amino group, respectively.
  • WSC water-soluble carbodiimide
  • EDC 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride
  • NHS N-hydroxysuccinimide
  • a method in which a dye is reacted and immobilized a method in which an antibody having a sulfonyl halide and an amino group and a fluorescent dye are reacted and immobilized; a method in which an antibody having an iodoacetamide and a thiol group and a fluorescent dye are reacted and immobilized; Cited .
  • the desired fluorescent dye is converted into the primary antibody or the secondary antibody. What is necessary is just to couple
  • FRET Fluorescence resonance energy transfer is a phenomenon in which a dye (referred to as “donor”) is excited by a light source in a system that detects molecules (donors and acceptor molecules) that interact in close proximity. Later, the energy is transferred to another dye (referred to as an “acceptor”). For energy transfer, the emission spectrum of the donor dye significantly overlaps with the excitation spectrum of the acceptor.
  • the extremely close parallel alignment of the two dyes is generally closer to 100 angstroms ( ⁇ ), preferably closer to 50 angstroms, more preferably closer to 10 angstroms (1 angstrom is 0.1 nanometer) equal.).
  • Essential for energy transfer between donor / acceptor pairs. FRET is usually based on the interaction between a donor dye and an acceptor dye, both fluorescent dyes.
  • the donor dye molecule In order to achieve resonance energy transfer as FRET, the donor dye molecule must absorb light and transfer it to the acceptor which is the second dye molecule through resonance of the excited electrons. In order to perform energy transfer, the wavelength of the donor's fluorescence emission must be lower than the excitation wavelength of the acceptor, ie the process must be energetically “downhill”.
  • fluorescent dyes used as donor molecules, acceptor molecules are fluorescein labels, for example 5- (and 6) -carboxyfluorescein, 5- or 6-carboxyfluorescein, 6- (fluorescein)- 5- (and 6) -carboxamide hexanoic acid and fluorescein isothiocyanate, Alexa Fluor dye, cyanine dye, eg Cy2, Cy3, Cy5, Cy7, optionally substituted coumarin ), R-phycoerythrin, allophycoerythrin, Texas Red and Princeston Red, and R-phycoerythrin and complexes of, for example, Cy5 or Texas Red That. Further, it may be a lanthanide complex, for example, a chelate fluorescent material such as terbium or eurobium.
  • fluorescein labels for example 5- (and 6) -carboxyfluorescein, 5- or 6-carboxyfluorescein, 6- (fluorescein)- 5- (and 6) -carboxamide he
  • the donor molecule and acceptor molecule are a FRET pair.
  • Any FRET pair may be used as the FRET pair in the present invention.
  • Preferred FRET pairs include, for example, Alexa Fluor647 / Cy5.5, HiLyte Fluor647 / Cy5.5, fluorescein isothiocyanate (FITC) / tetramethylrhodamine isothiocyanate (TRITC), R-phycoerythrin (R-PE). ) / Allophycocyanin (APC) pair group.
  • the R-PE / APC pair is very promising because 90% FRET efficiency can be achieved despite the dimensions of R-PE and APC. Furthermore, this FRET pair can be easily detected utilizing two common lasers in structures emitting at 488 and 632 nm. However, the FRET pair in the present invention is not limited to these examples.
  • a LANCE assay combining time-resolved fluorescence technology with Wallac fluorescence lanthanide chelate and FRET technology is known.
  • the donor label Eurobium chelate
  • the acceptor label Allophycocyanin
  • the excited energy of the eurobium chelate transfers energy to the acceptor at a short distance by non-radiative resonance energy transfer. Since the lanthanide that is a fluorescent substance is in an excited state for a long time, nonspecific background due to short-lived fluorescence that can be generated by direct excitation of the acceptor by excitation light can be avoided.
  • the metal thin film included in the “plasmon excitation sensor” described below is formed of a metal including gold, 1,3-dicroro-9,9-dimethyl-acidine-2- One-7-yl phosphate (DDAO phosphate) (Molecular Probes) is preferred.
  • DDAO phosphate 1,3-dicroro-9,9-dimethyl-acidine-2- One-7-yl phosphate
  • the autofluorescence wavelength of the donor molecule the greater the difference between the autofluorescence wavelength and the fluorescence wavelength of the acceptor fluorescent dye based on FRET, the easier it is to avoid the influence of the background signal, and as a result, highly accurate measurement is possible.
  • FRET fluorescence wavelength of the acceptor fluorescent dye based on FRET
  • the formed immune complex is qualitatively or quantitatively measured by exciting the fluorescence of the primary antibody constituting it with SPFS and then measuring the fluorescence development of the acceptor molecule of the secondary antibody enhanced by FRET. Can be assayed.
  • the fluorescent dye obtained through the step (a) into contact with the thin film surface of the plasmon excitation sensor having at least the transparent flat substrate and a metal thin film formed on one surface of the substrate, The donor molecule fluorescent dye bound to the antibody is excited.
  • a detection field is completely separated from the immune reaction field in a preferred embodiment.
  • the antigen-antibody reaction solution containing the formed immune complex is used as a thin film surface or spacer layer surface of the plasmon excitation sensor substrate. Or pass through. Accordingly, by appropriately providing a flow path system described later, it is possible to rapidly assay a large number of specimens including standard analytes of known concentrations, controls, and specimen specimens. Further, as a mode for high-throughput processing of the assay, ⁇ -TAS (Micro total analysis system) may be used.
  • SPFS Surface plasmon excitation fluorescence method
  • SPFS generates several dense waves (surface plasmons) on the metal thin film surface under the condition that the irradiated laser light undergoes total reflection attenuation (ATR) on the gold thin film surface, thereby doubling the photon amount of the irradiated laser light by several tens. Increased by several hundred times (electric field enhancement effect of surface plasmon), thereby enabling highly sensitive fluorescence measurement by efficiently exciting the fluorescent dye near the gold thin film.
  • the “plasmon excitation sensor” includes a transparent flat substrate and a metal thin film formed on one surface of the substrate, and further preferably has a spacer layer, and the spacer layer is the transparent flat plate of the metal thin film. It is desirable to form on the other surface which is not in contact with the substrate.
  • Such a plasmon excitation sensor has a substrate and a gold thin film, such as a sensor chip used in a Biacore system manufactured by GE Healthcare Biosciences, and further, a spacer layer is formed on the gold thin film. Also included.
  • the “transparent flat substrate” may be made of glass or plastic such as polycarbonate (PC) or cycloolefin polymer (COP), and preferably has a refractive index [n d ] of 1.40 to 2. And the thickness is preferably 0.01 to 10 mm, more preferably 0.5 to 5 mm, and the size (length ⁇ width) is not particularly limited.
  • PC polycarbonate
  • COP cycloolefin polymer
  • the glass transparent flat substrate is BK7 (refractive index [nd] 1.52) and LaSFN9 (refractive index [nd] 1.85) manufactured by SCHOTT AG, manufactured by Sumita Optical Glass Co., Ltd.
  • K-PSFn3 reffractive index [nd] 1.84
  • K-LaSFn17 reffractive index [nd] 1.88
  • K-LaSFn22 reffractive index [nd] 1.90
  • -LAL10 reffractive index [nd] 1.72 or the like is preferable from the viewpoint of optical characteristics and detergency.
  • the transparent flat substrate is preferably cleaned with acid and / or plasma before forming a metal thin film on the surface.
  • the cleaning treatment with acid it is preferable to immerse in 0.001 to 1N hydrochloric acid for 1 to 3 hours.
  • Examples of the plasma cleaning treatment include a method of immersing in a plasma dry cleaner (PDC200 manufactured by Yamato Scientific Co., Ltd.) for 0.1 to 30 minutes.
  • a plasma dry cleaner PDC200 manufactured by Yamato Scientific Co., Ltd.
  • the “metal thin film” is formed on one surface of the above “transparent flat substrate”, preferably made of at least one metal selected from the group consisting of gold, silver, aluminum, copper, and platinum, more preferably It is preferably made of gold and may be an alloy of these metals. Such metal species are preferable because they are stable against oxidation and increase in electric field due to surface plasmons increases. In addition, it is preferable that a group having affinity for gold as the surface metal thin film is bound to the primary antibody.
  • mercapto group (—SH), dithio group (—SS—), sulfo group (—SO 3 H), thiocarboxy group (—C (O) SH), dithiocarboxy group (—CSSH), amino group (—NH) 2 ) or a hydroxyl group (—OH).
  • a group having a particularly high affinity for gold is a mercapto group, a dithio group, a sulfo group, a thiocarboxy group, or a dithiocarboxy group, and particularly preferably a mercapto group.
  • the glass and the metal thin film can be bonded more firmly, so that a thin film of chromium, nickel chromium alloy or titanium is formed in advance. Is preferred.
  • Examples of methods for forming a metal thin film on a transparent flat substrate include sputtering, vapor deposition (resistance heating vapor deposition, electron beam vapor deposition, etc.), electrolytic plating, electroless plating, and the like. Since it is easy to adjust the thin film formation conditions, it is preferable to form a chromium thin film and / or a metal thin film by sputtering or vapor deposition.
  • the thickness of the metal thin film is preferably gold: 5 to 500 nm, silver: 5 to 500 nm, aluminum: 5 to 500 nm, copper: 5 to 500 nm, platinum: 5 to 500 nm, and alloys thereof: 5 to 500 nm.
  • the thickness of the thin film is preferably 1 to 20 nm.
  • gold 20-70 nm
  • silver 20-70 nm
  • aluminum 10-50 nm
  • copper 20-70 nm
  • platinum 20-70 nm
  • alloys thereof 10-70 nm
  • chromium The thickness of the thin film is more preferably 1 to 3 nm.
  • the thickness of the metal thin film is within the above range because surface plasmons are easily generated. Moreover, if it is a metal thin film which has such thickness, a magnitude
  • the “spacer layer” is formed on the other surface of the metal thin film not in contact with the “transparent flat substrate” for the purpose of preventing metal quenching of the fluorescent dye by the “metal thin film”.
  • it may be a SAM (Self Assembled Monolayer) or a dielectric.
  • streptavidin may be bound to the spacer layer or a streptavidinized portion may be included. Biotin bound to the primary antibody and its streptavidin specifically interact with each other to achieve “immobilization of the primary antibody by capture”.
  • SAM single molecule contained in “SAM”, usually a carboxyalkanethiol having about 4 to 20 carbon atoms (for example, available from Dojindo Laboratories Co., Ltd., Sigma Aldrich Japan Co., Ltd.), particularly preferably 10 -Carboxy-1-decanethiol is used.
  • Carboxyalkanethiol having 4 to 20 carbon atoms has properties such as little optical influence of SAM formed using it, that is, high transparency, low refractive index, and thin film thickness. Therefore, it is preferable.
  • the SAM formation method is not particularly limited, and a conventionally known method can be used.
  • a method of immersing a flat glass substrate having a metal thin film formed on an ethanol solution containing 10-carboxy-1-decanethiol (manufactured by Dojindo Laboratories).
  • the thiol group of 10-carboxy-1-decanethiol binds to the metal and is immobilized, and self-assembles on the surface of the gold thin film to form a SAM.
  • dielectric various inorganic substances that are optically transparent, or natural or synthetic polymers can be used. From the viewpoint of chemical stability, production stability, and optical transparency, silicon dioxide (SiO 2 ) Or titanium dioxide (TiO 2 ).
  • the thickness of the spacer layer made of a dielectric is usually 10 nm to 1 mm, and is preferably 30 nm or less, more preferably 10 to 20 nm from the viewpoint of resonance angle stability. On the other hand, it is preferably 200 nm to 1 mm from the viewpoint of electric field enhancement, and more preferably 400 nm to 1,600 nm from the stability of the effect of electric field enhancement.
  • Examples of the method for forming the spacer layer made of a dielectric include a sputtering method, an electron beam evaporation method, a thermal evaporation method, a formation method by a chemical reaction using a material such as polysilazane, or a spin coater.
  • a solution containing the fluorescent dye is dropped.
  • Spraying, coating, and the like there may be mentioned a method in which the following flow path is formed on the plasmon excitation sensor and a solution containing the fluorescent dye is brought into contact with the surface of the plasmon excitation sensor.
  • the “flow channel” is a rectangular parallelepiped or a tube that can efficiently deliver a small amount of a chemical solution and can change the liquid feeding speed or circulate in order to promote the reaction.
  • the vicinity of the place where the plasmon excitation sensor is installed preferably has a rectangular parallelepiped structure, and the vicinity of the place where the drug solution is delivered preferably has a tubular shape.
  • the plasmon excitation sensor part consists of a homopolymer or copolymer, polyethylene, polyolefin, etc. containing methyl methacrylate, styrene or the like as a raw material, and silicon rubber, Teflon (registered trademark), polyethylene, polypropylene, etc.
  • a polymer such as
  • the vertical and horizontal sections of the channel of the plasmon excitation sensor unit are independently about 100 nm to 1 mm.
  • a method of fixing the plasmon excitation sensor to the flow path in a small-scale lot (laboratory level), first, on the surface on which the metal thin film of the plasmon excitation sensor is formed, A dimethylsiloxane (PDMS) sheet is pressure-bonded so as to surround a portion where the metal thin film of the plasmon excitation sensor is formed, and then the polydimethylsiloxane (PDMS) sheet and the plasmon excitation sensor are closed with a screw or the like.
  • a method of fixing with a tool is preferred.
  • a gold substrate is formed on a plastic integrally molded product, or a separately manufactured gold substrate is fixed, and the gold surface is fixed. Further, after the dielectric layer, the fluorescent dye layer, and the ligand are immobilized, it can be manufactured by covering with a plastic integrally formed product corresponding to the top plate of the flow path. If necessary, the prism can be integrated into the flow path.
  • the “liquid feeding” is preferably the same as the solvent or buffer for diluting the specimen, and examples thereof include phosphate buffered saline (PBS) and Tris buffered saline (TBS), but are not particularly limited. It is not something.
  • PBS phosphate buffered saline
  • TBS Tris buffered saline
  • the temperature and time for circulating the liquid supply vary depending on the type of specimen and are not particularly limited, but are usually 20 to 40 ° C. ⁇ 1 to 60 minutes, preferably 37 ° C. ⁇ 5 to 15 minutes.
  • the second half of this assay consists of the plasmon excitation sensor with the above-mentioned immune complex immobilized on the other surface of the substrate on which the thin film is not formed, and laser light via a prism. , And the amount of fluorescence emitted from the excited secondary antibody fluorescent dye is measured. From the measurement result obtained in the above step, the antigen amount of the analyte contained in the specimen is calculated.
  • the laser light irradiation by the surface plasmon excitation fluorescence method is performed by transmitting the laser light to the immune complex via a prism from the other transparent substrate surface on which the metal thin film of the plasmon excitation sensor is not formed. Irradiation is performed, and thereby the fluorescence amount of the acceptor molecule emitted by the fluorescence resonance energy transfer (FRET) phenomenon from the excited donor molecule fluorescent dye of the primary antibody is determined.
  • FRET fluorescence resonance energy transfer
  • a calibration curve can be created by performing measurement with a target antigen at a known concentration, and the amount of target antigen in the sample can be calculated from the measured fluorescence amount based on the created calibration curve.
  • the surface plasmon is generated on the surface of the metal thin film by the laser light irradiation under the total reflection attenuation condition (ATR). Due to the electric field enhancement effect of surface plasmons, the fluorescent dye is excited by photons that are increased by several tens to several hundred times the amount of photons irradiated. The increase in photons due to the electric field enhancement effect depends on the refractive index of the glass serving as the substrate, the metal species and the film thickness of the metal thin film, but is usually about 10 to 20 times the increase in gold.
  • the fluorescent dye In the fluorescent dye, the electrons in the molecule are excited by light absorption, move to the first electronic excited state in a short time, and when returning from this state (level) to the ground state, the fluorescent dye has a wavelength corresponding to the energy difference. To emit.
  • an LD laser having a wavelength of 200 to 900 nm and 0.001 to 1,000 mW, or a semiconductor laser having a wavelength of 230 to 800 nm and 0.01 to 100 mW is preferable.
  • the “prism” is intended to allow the laser light through various filters to efficiently enter the plasmon excitation sensor, and the refractive index is preferably the same as that of the “transparent flat substrate”.
  • various prisms for which total reflection conditions can be set can be selected as appropriate, and therefore, there is no particular limitation on the angle and shape.
  • a 60-degree dispersion prism may be used.
  • Examples of such commercially available prisms include those similar to the above-mentioned commercially available “glass-made transparent flat substrate”.
  • optical filter examples include a neutral density (ND) filter and a diaphragm lens.
  • a neutral density (ND) filter is intended to adjust the amount of incident laser light. In particular, when a detector with a narrow dynamic range is used, it is preferable to use it for carrying out a highly accurate measurement.
  • the “polarizing filter” is used to convert the laser light into P-polarized light that efficiently generates surface plasmons.
  • “Cut filters” are external light (illumination light outside the device), excitation light (excitation light transmission component), stray light (excitation light scattering component in various places), plasmon scattering light (excitation light originated from plasmon A filter that removes various types of noise light such as scattered light generated by the influence of structures or deposits on the surface of the excitation sensor), autofluorescence of the donor fluorescent substrate, and examples thereof include interference filters and color filters. It is done.
  • the “condensing lens” is intended to efficiently collect the fluorescent signal on the detector, and may be an arbitrary condensing system.
  • a simple condensing system a commercially available objective lens (manufactured by Nikon Corporation or Olympus Corporation) used in a microscope or the like may be diverted.
  • the magnification of the objective lens is preferably 10 to 100 times.
  • the “SPFS detector” is preferably a photomultiplier (a photomultiplier manufactured by Hamamatsu Photonics) from the viewpoint of ultra-high sensitivity. Also, although the sensitivity is lower than these, a CCD image sensor capable of multipoint measurement is also suitable because it can be viewed as an image and noise light can be easily removed.
  • Table 1 shows plasmon excitation using Alexa Fluor (registered trademark) 647 (in Table 1, conditions 1 to 4) and HiLyte Fluor (registered trademark) 647 (in Table 1, conditions 5 to 6) as fluorescent dyes, respectively.
  • Alexa Fluor registered trademark
  • HiLyte Fluor registered trademark
  • Table 2 also shows that the plasmon excitation sensor has a large ratio between “Signal” and “Noise”, and the value of “Signal” that changes depending on the amount of fluorescent dye is relatively large compared to “Noise”, and has high sensitivity. It is shown that it is possible to measure easily.
  • the signal value when observed from the CCD was “Noise” (plasmon scattering noise), and 10 nM Alexa Fluor (registered trademark) 647 aqueous solution was sent.
  • the numerical value of the fluorescence signal when observed from the CCD is “Signal”.
  • the plasmon excitation sensor 1 in Table 2 is manufactured as follows.
  • a glass transparent flat substrate (S-LAL 10 manufactured by OHARA INC.) Having a refractive index [nd] of 1.72 and a thickness of 1 mm is plasma-cleaned, and a chromium thin film is formed on one surface of the substrate by sputtering. A gold thin film was further formed on the surface by sputtering.
  • the chromium thin film has a thickness of 1 to 3 nm, and the gold thin film has a thickness of 44 to 52 nm.
  • the plasmon excitation sensor 2 is manufactured in the same manner as the plasmon excitation sensor 1 except that the resistance heating vapor deposition method is used instead of sputtering in the method of manufacturing the plasmon excitation sensor 1, and the plasmon excitation sensor 1 further increases plasmon scattering.
  • the plasmon excitation sensor 3 drops a salt concentration adjusting solution in which polystyrene fine particles (manufactured by Polysciences Inc.) having an average particle size of about 100 nm are dropped on the surface of the plasmon excitation sensor 2, and is allowed to stand for several minutes. The fine particles are adhered to the surface of the sensor by washing with MilliQ water.
  • the immunoassay of the present invention in a detection field by a plasmon excitation sensor, a fluorescent dye possessed by a free secondary antibody or a secondary antibody non-specifically bound to the primary antibody by fluorescence measurement using a plasmon enhancement field, Since FRET does not appear, it does not emit fluorescence or remains very weak (FIG. 2). Therefore, the fluorescence background noise is at a low level. Since only fluorescence derived from the formed immune complex can be detected, even a very small amount of immune complex can be detected with high sensitivity by enhanced fluorescence emission. In particular, when the reaction field that forms an immune complex and the detection field based on fluorescence emission are separated as described above, optimization of various conditions and suppression of noise and background levels can be achieved very effectively. In this sense, the mode 1 or mode 2 in the step (a) is preferable.
  • the system of the present invention is a set of apparatuses for performing the assay method of the present invention using the plasmon excitation sensor. That is, at least, A primary antibody bound to a fluorescent dye serving as a donor molecule, which is immobilized on a metal thin film substrate of a plasmon excitation sensor, A secondary antibody to which a fluorescent dye serving as an acceptor molecule is bound, A plasmon excitation sensor, a light source for surface plasmon excitation fluorescence method, and a fluorescence detector, and cause a sandwich-type antigen-antibody reaction between both the primary antibody and the secondary antibody and the antigen contained in the specimen.
  • the plasmon excitation sensor emits light by fluorescence resonance energy transfer from the fluorescent dye of the primary antibody excited by irradiating the immune complex immobilized on the metal thin film substrate with laser light by the surface plasmon excitation fluorescence method.
  • An immunoassay system characterized in that the amount of the antigen is measured by measuring the amount of fluorescence of the acceptor molecule.
  • the “device” of the system of the present invention includes at least a light source, various optical filters, a prism, a cut filter, a condensing lens, and an SPFS detector. It is preferable to have a liquid feeding system combined with a plasmon excitation sensor when handling a sample liquid, a washing liquid, a labeled antibody liquid, or the like.
  • a liquid feeding system for example, a microchannel device (for example, ⁇ -TAS) connected to a liquid feeding pump may be used.
  • a surface plasmon resonance (SPR) detection unit that is, a photodiode as a light receiving sensor dedicated to SPR, an angle variable unit for adjusting the optimum angle of SPR and SPFS (to determine total reflection attenuation (ATR) conditions with a servomotor)
  • the photodiode and the light source can be synchronized with each other so that the angle can be changed by 45 to 85 °.
  • the resolution is preferably 0.01 ° or more.
  • Data processing for processing the information input to the SPFS detector A computer may also be included.
  • Preferred modes of the light source, the optical filter, the cut filter, the condensing lens, and the SPFS detection unit are the same as those described above.
  • liquid feed pump for example, a micro pump suitable for a small amount of liquid feed, a syringe pump with high feed accuracy and low pulsation, which is preferable but cannot be circulated, a simple and excellent handleability but a small amount of liquid feed
  • a tube pump may be difficult.
  • the kit of the present invention is characterized in that it is used for the immunoassay of the present invention, and in addition to the primary antibody and the secondary antibody, all the necessary antibodies are required for carrying out the assay of the present invention. It is preferable to include.
  • kits Including at least a plasmon excitation sensor, a primary antibody bound to a fluorescent dye serving as a donor molecule, which is an antibody immobilized on the surface of the metal thin film substrate, and a secondary antibody bound to a fluorescent dye serving as an acceptor molecule,
  • a kit used for carrying out the step of forming an immune complex by causing a sandwich-type antigen-antibody reaction between the primary antibody, the antigen in the specimen, and the secondary antibody is shown. It is.
  • the metal thin film that is a member of the plasmon excitation sensor is formed of at least one metal selected from the group consisting of gold, silver, aluminum, copper, and platinum.
  • a more preferable metal thin film is a gold thin film.
  • the plasmon excitation sensor is composed of the metal thin film and the transparent flat substrate, and further has a spacer layer, and the spacer layer is formed on the other surface of the metal thin film that is not in contact with the transparent flat substrate.
  • the embodiment is preferred.
  • the configuration, installation method, significance, and the like of such a spacer layer are as described above.
  • Such a spacer layer is preferably a SAM (Self Assembled Monolayer).
  • kits As a component of the “kit” of the present invention, specifically, in addition to a plasmon excitation sensor in which a metal thin film is formed on one surface of a transparent flat substrate, a lysis solution or dilution solution for dissolving or diluting a specimen; antibody Various reaction reagents and washing reagents for reacting the analyte with the analyte, and various equipment or materials required for carrying out the assay method of the present invention can also be included. Further, as a kit element, a standard material for preparing a calibration curve, a manual, a necessary set of equipment such as a microtiter plate capable of simultaneously processing a large number of samples may be included.
  • the FRET technique is applied by labeling two types of antibodies (primary and secondary antibodies that are binding partners) with fluorescent dyes that form a FRET donor-acceptor pair.
  • primary and secondary antibodies that are binding partners
  • fluorescent dyes that form a FRET donor-acceptor pair.
  • an immune complex is formed between the antigen and the antibody in the specimen. If the binding partner and the analyte are relatively small in such an immune complex, the fluorophores may come close to each other, resulting in the desired measurable FRET signal. Be expected.
  • a short distance (1-10 nm) between the donor molecule and the acceptor molecule is required as described above.
  • the distance between the donor molecule and the acceptor molecule present in the formed immune complex is further set to about 10 nm.
  • the fluorescent dyes of the two antibodies need to be oriented (or juxtaposed) with each other so that they are suitable for FRET. A device for realizing such precise molecular orientation is required.
  • a complete antibody is a large Y-type protein molecule, and due to its length (30-40 nm) and the flexibility of the antibody hinge region, antibody molecules will be conjugated at relatively large intervals.
  • Antibody flexibility may reduce the possibility of energy transfer between a pair of dyes bound to side-by-side antibodies.
  • the size of the antibody or fluorescent dye may interfere with energy transfer through the negative steric effect exerted.
  • the fluorescent dye moiety can be attached to a different part of the antibody molecule. Depending on such sites, the spatial orientation of the dye in the antibody molecule can be advantageous or inconvenient with respect to energy transfer efficiency.
  • the parallel May not necessarily be sufficient to achieve effective energy transfer between the dyes attached to the prepared antibody, eg, between the fluorescent dye-conjugated antibodies.
  • the donor and acceptor molecules must be in close proximity, typically 0.2 to 10 nm.
  • the following measures can be taken as a measure for obtaining the FRET signal as a desired intensity.
  • the antibody is fragmented (Fab) and the molecular size is reduced to reduce the fluctuation of the molecular structure, thereby reducing FRET inhibition.
  • the distance between the labeled fluorescent dyes can be shortened.
  • the antibody is reduced, and fluorescent labeling is performed using the SH group appearing in the Fc part of the antibody.
  • the labeling rate per molecule may be lower than the method using amino groups, but since the position of the SH group is fixed, the labeling position can be determined (if there is another free SH) This is also labeled).
  • the fluorescent dye can be labeled near the center of the antibody molecule, the distance between the dyes can be shortened.
  • Such a binding reactive group makes it possible to adjust the alignment between the antibodies so as to increase the possibility of energy transfer between the dyes.
  • Use of such an antibody set may dramatically increase the probability of energy transfer compared to the use of an antibody set without a binding reactive group.
  • Spatial structure here refers not only to the spacing between the dyes but also to their relative orientation.
  • Modulating the spatial structure between antibodies includes modulating and stabilizing the spatial structure of the dye.
  • the conjugating reactive groups can bring the dyes into an interval within 10 nm of each other, more preferably within an interval of within 5 nm, and most preferably within an interval of within 2 nm of each other.
  • the linking reactive group is small, for example smaller than 10 kilodalton (kDa), preferably smaller than 5 kDa, more preferably smaller than 2 kDa, or most preferably smaller than 1 kDa (US Pat. ).
  • Biotin- (strept) avidin system is preferable as an example of the above-mentioned binding reactive group added to an antibody and adjusting the spatial arrangement of fluorescent dyes. This conjugation reactive group is advantageous to achieve close spacing between the fluorescent dye pairs.
  • Biotin can bind proteins with small molecules having a molecular weight of only 244 daltons (Da).
  • Da daltons
  • DNA or polynucleotide of an appropriate size may be introduced as a binding reaction group as described below, and hybridization thereof may be used.
  • Method 1 using DNA A primary antibody is labeled with a DNA-donor dye, and a secondary antibody is labeled with a complementary strand DNA-acceptor molecule. 2) Immobilize the primary antibody on the substrate. 3) The primary antibody is reacted with an antigen and then a secondary antibody to form an immune complex, which is immobilized on the substrate via the primary antibody. Alternatively, the immune complex may be immobilized by bringing a reaction solution of the secondary antibody and the specimen (a reaction solution containing a complex of the antigen and the secondary antibody) into contact with the substrate.
  • conditions conditions such as salt concentration and temperature
  • conditions that “immune complexes are formed but DNA hybridization does not occur” are set. For example, when the salt concentration is low, hybridization does not occur.
  • 4) Remove unreacted secondary antibody with wash buffer.
  • conditions for example, salt concentration, temperature
  • the salt concentration is preferably about 150 mM.
  • Hybridization occurs between the primary antibody DNA-donor dye and the secondary antibody complementary-strand DNA-acceptor dye, and FRET is expressed between the donor dye and the acceptor dye.
  • DNA-complementary strand DNA hybridization need not be specific (for example, as in SNP analysis), and may be within a certain distance from the nearby one.
  • 1) and 2) are the same, but the steps after 3) may be changed as follows.
  • the primary antibody is reacted with an antigen and then a secondary antibody to form an immune complex, which is immobilized on the substrate via the primary antibody.
  • the immune complex may be immobilized by bringing a reaction solution of the secondary antibody and the specimen (a reaction solution containing a complex of the antigen and the secondary antibody) into contact with the substrate.
  • the DNA and the complementary strand DNA hybridize regardless of the presence or absence of immune complex formation.
  • Set conditions for example, salt concentration, temperature
  • Unreacted secondary antibody not forming an immune complex is removed with a washing buffer. At this time, the hybridization between the DNA forming the immune complex and the complementary strand DNA is once dissociated. 5) Set conditions (for example, salt concentration, temperature) for “maintaining immune complexes and allowing DNA to hybridize”, and apply the conditions. 6) The DNA and the complementary strand DNA hybridize with the nearest neighbors.
  • the primary antibody and the DNA labeled with the secondary antibody that are closer to each other due to the formation of an immune complex preferentially hybridize, and FRET is expressed between the donor dye and the acceptor dye.
  • the above 1) to 4) are the same, but the steps after 5) are as follows.
  • a buffer solution containing a protein denaturant (such as urea) and having a high salt concentration is developed on the substrate.
  • a protein denaturant such as urea
  • the DNA on the substrate and the complementary strand DNA are not affected by the three-dimensional structure and hybridize with high probability.
  • the primary antibody does not come off if it is immobilized on the substrate by a covalent bond. Also, DNA is not detached from the substrate even under denaturing conditions as long as it is covalently bound to the antibody molecule. In contrast, the secondary antibody may be released.
  • the complementary strand DNA that has been bound to the secondary antibody may be removed from the antibody molecule.
  • the primary antibody DNA-donor dye immobilized on the substrate and the secondary antibody-derived complementary DNA-acceptor dye are hybridized, and FRET is expressed between the donor dye and the acceptor dye.
  • the primary antibody, specimen and secondary antibody are reacted in advance, and the formed immune complex is then contacted with a (plasmon excitation sensor) metal thin film substrate to bind the primary antibody of the immune complex onto the substrate.
  • a (plasmon excitation sensor) metal thin film substrate to bind the primary antibody of the immune complex onto the substrate.
  • conditions for example, salt concentration, temperature
  • DNA is hybridized after the immobilization. do it.
  • a preferred form of the assay of the present invention is an embodiment in which an immune reaction field and a fluorescence detection field are separated. That is, in the immune reaction field, the primary antibody labeled with the donor molecule recognizes and binds to the target antigen contained in the specimen, and the secondary antibody labeled with the acceptor molecule also recognizes another epitope of the antigen. Binding, resulting in the formation of a sandwich-type immune complex.
  • the reaction product of these antigens and both antibodies is then applied to a plasmon excitation sensor.
  • the binding group of the primary antibody Fc base is captured by the tethering binding group provided on the surface of the metal thin film substrate, and the sandwich-type immune complex is immobilized on the metal thin film substrate (the above step (a )).
  • a washing operation with a washing buffer may be performed.
  • the detection field of the assay includes a glass transparent flat substrate, a metal thin film formed on one surface of the substrate, and a spacer layer formed on the other surface of the thin film that is not in contact with the substrate.
  • the sandwich-type immune complex that is immobilized in contact with the surface on the spacer layer side is irradiated with a laser beam via a prism from the other surface of the substrate on which the thin film is not formed.
  • Primary antibody donor molecules emit light when excited by surface plasmons.
  • a fluorescent dye (acceptor molecule) bound to the secondary antibody by FRET expression is excited to emit light. Since only the immune complex thus formed emits enhanced fluorescence, this is detected and the amount of fluorescence is measured (step (b) above).
  • the substrate thus obtained is immersed in an ethanol solution containing 1 mM 10-carboxy-1-decanethiol for 24 hours or more to form a SAM (Self Assembled Monolayer) on one side of the gold thin film. did.
  • the substrate was removed from the solution, washed with ethanol and isopropanol, and then dried with an air gun.
  • a polydimethylsiloxane (PDMS) sheet having a flow path height of 0.5 mm is provided on the surface of the SAM, and the substrate is arranged so that the SAM surface is inside the flow path (however, the silicon rubber spacer is used for liquid feeding).
  • the pressure-sensitive adhesive sheet was pressed from the outside of the flow path, and the flow path sheet and the plasmon excitation sensor were fixed with screws.
  • the obtained biotinylated anti-AFP monoclonal antibody solution and the streptavidin-labeled Alexa Fluor (registered trademark) 647 (Molecular Probes) solution are mixed and reacted by stirring at 4 ° C. for 60 minutes. It was. Subsequently, the unreacted antibody and the unreacted enzyme were purified using a molecular weight cut filter (manufactured by Nippon Millipore) to obtain an Alexa Fluor (registered trademark) 647-labeled anti-AFP monoclonal antibody solution. The obtained antibody solution was stored at 4 ° C. after the protein amount was quantified.
  • the Cy5.5 (registered trademark) -labeled anti-AFP monoclonal antibody solution was obtained by purifying the unreacted antibody and the unreacted enzyme using a molecular weight cut filter (manufactured by Nippon Millipore). The obtained antibody solution was stored at 4 ° C. after protein quantification.
  • Example 1 (Production of plasmon excitation sensor) A plasmon excitation sensor is prepared in the same manner as in [Preparation Example 1], and the primary antibody is immobilized.
  • ultrapure water was circulated with a peristaltic pump at room temperature and a flow rate of 500 ⁇ L / min for 10 minutes, followed by PBS for 20 minutes.
  • 5 mL of PBS containing 50 mM N-hydroxysuccinimide (NHS) and 100 mM water-soluble carbodiimide (WSC) was fed and circulated for 20 minutes, and then the method of [Preparation Example 2]
  • NHS N-hydroxysuccinimide
  • WSC water-soluble carbodiimide
  • a non-specific adsorption prevention treatment is performed by circulating the solution for 30 minutes in PBS buffered saline containing 1% bovine serum albumin (BSA), and a plasma excitation sensor is prepared using SPFS. The assay was performed.
  • BSA bovine serum albumin
  • Washing step Washing was performed by circulating TBS containing 0.05% by weight of Tween 20 for 20 minutes.
  • blank fluorescence is used, LD laser is used as a light source, laser light having a wavelength of 635 nm is adjusted with an optical filter: (Sigma Kogyo Co., Ltd.), and the amount of photons is adjusted.
  • a cut filter (Sigma Kogyo Co., Ltd.), a 20 ⁇ objective lens as a condenser lens It was detected by a CCD image sensor (manufactured by Texas Instruments) using Nikon Corporation.
  • AFP ⁇ -fetoprotein
  • Example 2 (Production of plasmon excitation sensor) It was produced in the same manner as in Example 1.
  • Washing step Washing was performed by circulating TBS containing 0.05% by weight of Tween 20 for 20 minutes.
  • blank fluorescence is used, LD laser is used as a light source, laser light having a wavelength of 635 nm is adjusted with an optical filter: (Sigma Kogyo Co., Ltd.), and the amount of photons is adjusted.
  • a cut filter (Sigma Kogyo Co., Ltd.), a 20 ⁇ objective lens as a condenser lens It was detected by a CCD image sensor (manufactured by Texas Instruments) using Nikon Corporation.
  • AFP ⁇ -fetoprotein
  • Washing step Washing was performed by circulating TBS containing 0.05% by weight of Tween 20 for 10 minutes.
  • ultrapure water was circulated with a peristaltic pump at room temperature and a flow rate of 500 ⁇ L / min for 10 minutes followed by PBS for 20 minutes.
  • 5 mL of PBS containing 50 mM N-hydroxysuccinimide (NHS) and 100 mM water-soluble carbodiimide (WSC) was fed and circulated for 20 minutes, followed by anti- ⁇ -fetoprotein (AFP) monoclonal.
  • the primary antibody was solid-phased on the SAM by circulating 2.5 mL of an antibody (1D5, 2.5 mg / mL, manufactured by Japan Medical Clinical Laboratory Laboratories) solution for 30 minutes.
  • a non-specific adsorption prevention treatment is performed by circulating the solution for 30 minutes in PBS buffered saline containing 1% bovine serum albumin (BSA), and a plasma excitation sensor is prepared using SPFS. The assay was performed.
  • BSA bovine serum albumin
  • Washing step Washing was performed by circulating TBS containing 0.05% by weight of Tween 20 for 20 minutes.
  • blank fluorescence is used, LD laser is used as a light source, laser light having a wavelength of 635 nm is adjusted with an optical filter: (Sigma Kogyo Co., Ltd.), and the amount of photons is adjusted.
  • a cut filter (Sigma Kogyo Co., Ltd.), a 20 ⁇ objective lens as a condenser lens It was detected by a CCD image sensor (manufactured by Texas Instruments) using Nikon Corporation.
  • AFP ⁇ -fetoprotein
  • Washing step Washing was performed by circulating TBS containing 0.05% by weight of Tween 20 for 10 minutes.
  • Example 2 was obtained by adding a washing operation to the assay process of Example 1, but the assay signal was slightly lower than that of Example 1 due to the addition of the washing operation. However, since the assay signal noise hardly changes, it is considered that there is almost no increase in the assay signal due to nonspecific adsorption in Example 1. From this, it is considered that the decrease in the assay signal originates from the fact that the equilibrium state of the immune complex changes due to the replacement of the reaction solution by the washing operation, and the secondary antibody gradually dissociates. .
  • the assay signal is reduced by about 20% compared to the assay signal of the fluorescence labeled SPFS measurement shown in Comparative Example 1. This is considered to be the effect of insufficient FRET efficiency, and further improvement can be expected by optimizing the FRET efficiency.
  • the assay method of the present invention is a method capable of detecting a target antigen with high sensitivity and high accuracy, for example, even a trace amount of tumor marker contained in blood can be detected, From this result, the presence of a preclinical noninvasive cancer (carcinoma in situ) that cannot be detected by palpation or the like can be predicted with high accuracy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)

Abstract

L'invention porte sur un immunodosage utilisant un transfert d'énergie par résonance de fluorescence (FRET) et une spectroscopie par fluorescence améliorée par champ de plasmons de surface (SPFS). L'invention porte spécifiquement sur un procédé d'immunodosage pour mesurer la quantité d'un antigène dans un échantillon à l'aide d'un anticorps primaire auquel est conjugué un colorant fluorescent qui sert de molécule donneuse et un second anticorps auquel est conjugué un colorant fluorescent qui sert de molécule acceptrice. L'immunodosage comprend au moins les étapes suivantes (a) et (b), consistant : (a) à permettre à une réaction antigène-anticorps, entre l'antigène contenu dans l'échantillon et à la fois les anticorps primaire et secondaire, de se produire et immobiliser un complexe immunologique, comprenant les anticorps et l'antigène pris en sandwich entre les anticorps, sur un support en film mince métallique ; et (b) à irradier le complexe immunologique produit à l'étape précédente par un faisceau laser au moyen de SPFS et à mesurer la quantité de fluorescence émise par la molécule acceptrice par suite d'un FRET à partir du colorant fluorescent de molécule donneuse excité dans l'anticorps primaire. L'invention porte également sur un système et un kit de dosage pour l'immunodosage.
PCT/JP2009/071331 2008-12-24 2009-12-22 Immunodosage utilisant un transfert d'énergie par résonance de fluorescence et des plasmons de surface Ceased WO2010074083A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010544084A JP5720248B2 (ja) 2008-12-24 2009-12-22 表面プラズモンおよび蛍光共鳴エネルギー転移を利用した免疫アッセイ

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008328109 2008-12-24
JP2008-328109 2008-12-24

Publications (1)

Publication Number Publication Date
WO2010074083A1 true WO2010074083A1 (fr) 2010-07-01

Family

ID=42287691

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/071331 Ceased WO2010074083A1 (fr) 2008-12-24 2009-12-22 Immunodosage utilisant un transfert d'énergie par résonance de fluorescence et des plasmons de surface

Country Status (2)

Country Link
JP (1) JP5720248B2 (fr)
WO (1) WO2010074083A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012026879A (ja) * 2010-07-23 2012-02-09 Konica Minolta Holdings Inc 蛍光標識剤、並びにこれを用いた結合体及びバイオアッセイ法
JP2012032281A (ja) * 2010-07-30 2012-02-16 Konica Minolta Holdings Inc プラズモン励起センサおよび該センサを用いたアッセイ法
JP2012058169A (ja) * 2010-09-13 2012-03-22 Konica Minolta Holdings Inc プラズモン励起センサを用いるアッセイ方法及びプラズモン励起センサ
JPWO2011096394A1 (ja) * 2010-02-02 2013-06-10 コニカミノルタホールディングス株式会社 アナライト検出プローブおよびこれを用いたアナライトの検出方法
GB2511761A (en) * 2013-03-11 2014-09-17 Cancer Rec Tech Ltd Methods for detecting molecules in a sample
JP2015502551A (ja) * 2011-12-23 2015-01-22 フォルシュングスツェントルム ユーリッヒ ゲゼルシャフ Ａβ凝集体の選択的定量化方法
JP2018189523A (ja) * 2017-05-08 2018-11-29 国立大学法人電気通信大学 計測用デバイス及び計測センサ
JP2019194581A (ja) * 2018-05-04 2019-11-07 コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーションＫｏｒｅａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｂｕｓｉｎｅｓｓ Ｆｏｕｎｄａｔｉｏｎ 多層ナノワイヤ複合体及びその製造方法
CN111024942A (zh) * 2019-11-27 2020-04-17 北京农业智能装备技术研究中心 一种免疫层析试纸条的高灵敏检测方法
CN113552345A (zh) * 2021-06-10 2021-10-26 深圳大学 一种基于免疫荧光增强的外泌体定量检测方法
US11650205B2 (en) 2019-02-11 2023-05-16 Qanikdx Oü Selective optical detection of organic analytes in liquids
CN116263404A (zh) * 2021-12-14 2023-06-16 深圳先进技术研究院 一种蛋白质液相分离的探测方法及其应用
JP2024524931A (ja) * 2021-06-17 2024-07-09 エフ． ホフマン－ラ ロシュ アーゲー 脂質層上で免疫センシングするための方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006512562A (ja) * 2002-01-31 2006-04-13 セント・ルイス・ユニバーシテイ 核酸結合因子の補調節因子を検出し定量するための、迅速かつ鋭敏なアッセイ
JP2009080011A (ja) * 2007-09-26 2009-04-16 Fujifilm Corp 蛍光検出方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006512562A (ja) * 2002-01-31 2006-04-13 セント・ルイス・ユニバーシテイ 核酸結合因子の補調節因子を検出し定量するための、迅速かつ鋭敏なアッセイ
JP2009080011A (ja) * 2007-09-26 2009-04-16 Fujifilm Corp 蛍光検出方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOMARALA ET AL: "Enhanced Forster resonance energy transfer between the CdTe quantum dots in proximity to gold nanoparticles", PROC.OF SPIE, vol. 6641, 2007, pages 66410Y-1 - 66410Y-8 *
VAREIRO ET AL: "Surface Plasmon Fluorescence Measurements of Human Chorionic Gonadotrophin: Role of Antibody Orientation in Obtaining Enhanced Sensitivity and Limit of Detection", ANAL. CHEM., vol. 77, 2005, pages 2426 - 2431 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2011096394A1 (ja) * 2010-02-02 2013-06-10 コニカミノルタホールディングス株式会社 アナライト検出プローブおよびこれを用いたアナライトの検出方法
JP2015129773A (ja) * 2010-02-02 2015-07-16 コニカミノルタ株式会社 アナライト検出プローブ
JP2012026879A (ja) * 2010-07-23 2012-02-09 Konica Minolta Holdings Inc 蛍光標識剤、並びにこれを用いた結合体及びバイオアッセイ法
JP2012032281A (ja) * 2010-07-30 2012-02-16 Konica Minolta Holdings Inc プラズモン励起センサおよび該センサを用いたアッセイ法
JP2012058169A (ja) * 2010-09-13 2012-03-22 Konica Minolta Holdings Inc プラズモン励起センサを用いるアッセイ方法及びプラズモン励起センサ
JP2019015738A (ja) * 2011-12-23 2019-01-31 フォルシュングスツェントルム ユーリッヒ ゲゼルシャフ Ａβ凝集体の選択的定量化方法
JP2015502551A (ja) * 2011-12-23 2015-01-22 フォルシュングスツェントルム ユーリッヒ ゲゼルシャフ Ａβ凝集体の選択的定量化方法
GB2511761A (en) * 2013-03-11 2014-09-17 Cancer Rec Tech Ltd Methods for detecting molecules in a sample
JP2018189523A (ja) * 2017-05-08 2018-11-29 国立大学法人電気通信大学 計測用デバイス及び計測センサ
JP2019194581A (ja) * 2018-05-04 2019-11-07 コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーションＫｏｒｅａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｂｕｓｉｎｅｓｓ Ｆｏｕｎｄａｔｉｏｎ 多層ナノワイヤ複合体及びその製造方法
US11156604B2 (en) 2018-05-04 2021-10-26 Korea University Research And Business Foundation Multilayer nanowire complex and method of preparing the same
US11650205B2 (en) 2019-02-11 2023-05-16 Qanikdx Oü Selective optical detection of organic analytes in liquids
US11899011B2 (en) 2019-02-11 2024-02-13 Qanikdx Ou Selective optical detection of organic analytes in liquids
CN111024942A (zh) * 2019-11-27 2020-04-17 北京农业智能装备技术研究中心 一种免疫层析试纸条的高灵敏检测方法
CN111024942B (zh) * 2019-11-27 2023-06-02 北京农业智能装备技术研究中心 一种免疫层析试纸条的高灵敏检测方法
CN113552345A (zh) * 2021-06-10 2021-10-26 深圳大学 一种基于免疫荧光增强的外泌体定量检测方法
CN113552345B (zh) * 2021-06-10 2024-02-09 深圳大学 一种基于免疫荧光增强的外泌体定量检测方法
JP2024524931A (ja) * 2021-06-17 2024-07-09 エフ． ホフマン－ラ ロシュ アーゲー 脂質層上で免疫センシングするための方法
CN116263404A (zh) * 2021-12-14 2023-06-16 深圳先进技术研究院 一种蛋白质液相分离的探测方法及其应用

Also Published As

Publication number Publication date
JP5720248B2 (ja) 2015-05-20
JPWO2010074083A1 (ja) 2012-06-21

Similar Documents

Publication Publication Date Title
JP5720248B2 (ja) 表面プラズモンおよび蛍光共鳴エネルギー転移を利用した免疫アッセイ
Mariani et al. Surface plasmon resonance applications in clinical analysis
US20230213507A1 (en) Optical probe for bio-sensor, optical bio-sensor including optical probe, and method for manufacturing optical probe for bio-sensor
JP5652393B2 (ja) Ｓｐｆｓ−ｌｐｆｓ系による測定方法に供するプラズモン励起センサおよびアッセイ法
JP5994890B2 (ja) アナライト検出プローブ
JP5428322B2 (ja) プラズモン励起センサを用いたアッセイ法
Reiner et al. Biosensor platform for parallel surface plasmon-enhanced epifluorescence and surface plasmon resonance detection
US20210132053A1 (en) Imaging assays
Chen et al. Near-infrared surface plasmon resonance sensor with a graphene-gold surface architecture for ultra-sensitive biodetection
Iwanaga Highly sensitive wide-range target fluorescence biosensors of high-emittance metasurfaces
JP5006459B1 (ja) 標識用複合粒子
EP2224241B1 (fr) Support pour une utilisation dans la mesure d'une substance à analyser, et son procédé de fabrication
Knoll et al. Supramolecular functional interfacial architectures for biosensor applications
JP5516198B2 (ja) プラズモン励起センサチップおよびこれを用いたプラズモン励起センサ、並びにアナライトの検出方法
JP5660035B2 (ja) 融合タンパク質含有集合体、その製造方法及び該集合体を用いたアッセイ法
JP2013145139A (ja) Ｓｐｆｓ（表面プラズモン励起増強蛍光分光法）を用いたミオグロビンの免疫学的測定法
US9134235B2 (en) SPFS sensor equipped with mechanism purifying non-specifically adsorptive contaminants
WO2010041736A1 (fr) Procédé de dosage utilisant un plasmon de surface
JP2011127991A (ja) プラズモン励起センサおよび該センサを用いたアッセイ法
JP2012042233A (ja) Ｓｐｆｓ（表面プラズモン励起増強蛍光分光法）により測定される蛍光シグナルの補正方法およびこれを用いたアッセイ方法、並びにこれらの方法に用いられる構造体および表面プラズモン共鳴センサー
JP2010091527A (ja) 表面プラズモンを利用したアッセイ法
JP5298877B2 (ja) プラズモン励起センサを用いたアッセイ法
JP2013181889A (ja) Ｓｐｆｓ（表面プラズモン励起増強蛍光分光法）を用いたｃｋ−ｍｂ（クレアチンキナーゼアイソザイムｍｂ）の免疫学的測定法
JP5245125B2 (ja) 表面プラズモンを利用したアッセイ法
JP5169891B2 (ja) 表面プラズモンを利用したアッセイ法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09834884

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2010544084

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09834884

Country of ref document: EP

Kind code of ref document: A1